Docetaxel as neo-adjuvant therapy for radically treatable stage III non-small cell lung cancer: early results of an international phase III study

Lung Cancer. 2001 Dec:34 Suppl 4:S21-3. doi: 10.1016/s0169-5002(01)00389-0.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / radiotherapy
  • Carcinoma, Non-Small-Cell Lung / surgery
  • Docetaxel
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / radiotherapy
  • Lung Neoplasms / surgery
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Paclitaxel / analogs & derivatives*
  • Paclitaxel / therapeutic use*
  • Survival Analysis
  • Taxoids*

Substances

  • Antineoplastic Agents, Phytogenic
  • Taxoids
  • Docetaxel
  • Paclitaxel